FDA’s Activism Changes the Landscape In Treatment, Trials of Squamous NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Citing a dramatic improvement in overall survival in second-line squamous non-small cell lung cancer, FDA rapidly approved the Bristol-Myers Squibb drug Opdivo (nivolumab).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login